Page 47 - Micron News Today

This in-depth study examines how previous immunity impacts the effectiveness of COVID-19 booster vaccinations and susceptibility to Omicron breakthrough infections. The research highlights the significant role of individual immune histories in shaping both humoral and cellular responses to SARS-CoV-2, urging for more tailored vaccine strategies.

An adapted COVID-19 vaccine from Moderna (Spikevax) that targets the Omicron XBB 1.5 subvariant, has today been authorized by the Medicines and Healthcare products Regulatory Agency (MHRA) after it was found to meet the UK regulator's standards of safety, quality and effectiveness.

What are the side effects of the new COVID-19 vaccines? Are COVID vaccines still free? Get the facts about the cost, eligibility and more.

Researchers have isolated a new SARS-CoV-2 Omicron subvariant, BA.2.86, revealing its ability to escape neutralizing antibodies five-fold greater than its ancestor strain. Despite its enhanced immune evasion capabilities, BA.2.86 has not shown a significant difference in spread compared to other current variants.

PLI Scheme: Last month, 40 proposals worth Rs. 5,000 crore were received by the ministry of electronics and IT under the IT Hardware Production Linked Incentive (PLI) 2.0 scheme, although fixed benefit limits mean not all offers will be eligible for the federal monetary support.

A team from the UNIGE and the HUG analyzed the contacts of 50,000 COVID-19 positive cases. Immunity following vaccination provides better protection for those around you.

The dire predictions didn’t come true. Legislative Democrats did not steal Oregonians’ income tax kicker.

India is expected to approve investment proposals worth ₹4,000 crore under the revised IT hardware Production Linked Incentive (PLI) scheme. Last month, the ministry of electronics and IT received 40 proposals amounting to ₹5,000 crore, but not all will be approved due to budget constraints.

The US Food and Drug Administration (FDA) has given the green light to newly developed COVID-19 vaccines of Pfizer and Moderna.

UK study reveals COVID-19 vaccination effectively boosts anti-S antibody levels and reduces symptom severity post-infection, irrespective of the viral variant involved. High antibody levels are linked to quicker viral clearance, suggesting reduced transmission risk.